// App-Quantinova.ai

: Bone morphogenetic protein 9 protects against neonatal hyperoxia-induced impairment of lung development, inflammation and fibrosis

Researchers

Presenter

  • Xueyu Chen

Principal Investigators

  • Mar Orriols

  • El Houari Laghmani

  • Annemarie M. Hoogeboom

  • Anne C. B. Hogen-Esch

  • Pieter S. Hiemstra

  • Gert Folkerts

  • Marie-Jos Goumans

  • Peter ten Dijke

  • Nicholas Morrell

  • Gerry T. M. Wagenaar

  • Frans J. Walther

Medical Centers

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

  • Department of Molecular Cell Biology, Cancer Genomics Centre Netherlands, Leiden University Medical Center, Leiden, Netherlands

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

  • Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

  • Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth Hospitals, Cambridge, United Kingdom

  • Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States of America

Locations

  • Netherlands

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Pulmonary arterial hypertension

  • Infant Respiratory Distress Syndrome

  • Hypertension

Biomarkers

  • Activin A receptor type II-like 1

  • Bone Morphogenetic Protein Receptor Type 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved